Platelet-rich plasma inhibits inflammation, apoptosis, and the NLRP3/Caspase-1 pathway and induces matrix metalloproteinases and proliferation of IL-1β-induced articular chondrocytes by downregulating T-box transcription factor 3. (31st May 2022)
- Record Type:
- Journal Article
- Title:
- Platelet-rich plasma inhibits inflammation, apoptosis, and the NLRP3/Caspase-1 pathway and induces matrix metalloproteinases and proliferation of IL-1β-induced articular chondrocytes by downregulating T-box transcription factor 3. (31st May 2022)
- Main Title:
- Platelet-rich plasma inhibits inflammation, apoptosis, and the NLRP3/Caspase-1 pathway and induces matrix metalloproteinases and proliferation of IL-1β-induced articular chondrocytes by downregulating T-box transcription factor 3
- Authors:
- Zhuo, Feng
Li, Jun
Wang, Yong-Hong
Li, Ming
Song, Fang-Fei
Liu, Yu-Liang
Tao, Zong-Yu - Abstract:
- Objectives: Osteoarthritis (OA) is a chronic joint disease characterized by osteoproliferation and the degeneration and destruction of articular cartilage. Platelet-rich plasma (PRP) is rich in various growth factors that have been reported to promote bone defect repair. This study examined the specific role and mechanism of PRP in OA. Methods: OA model cells were created by treating articular chondrocytes with IL-1β. After treatment of the model cells with PRP or/and a T-box transcription factor 3 (TBX3)-overexpression plasmid, TBX3 expression was monitored via RT-qPCR, western blotting, and immunofluorescence assays. IL-1β, IL-33, and Caspase-3 levels were detected with ELISA kits. Levels of NLRP3, Caspase-1, MMP9, MMP13, and COL2A1 expression were evaluated by western blotting, and cell proliferation was assessed by the CCK-8 assay. Results: Our results showed that TBX3 expression was upregulated in IL-1β-induced articular chondrocytes. IL-1β stimulation induced inflammation and the production of matrix metalloproteinases, activated Caspase-3 and the NLRP3/Caspase-1 pathway, inhibited the proliferation of articular chondrocytes; however, all those affects mediated by IL-1β could be markedly reversed by PRP. We also found that PRP alleviated IL-1β-induced inflammation, apoptosis, and extracellular matrix degradation in articular chondrocytes by inhibiting TBX3. Our findings suggest that PRP alleviates OA progression in vitro by downregulating TBX3. Conclusion: PRPObjectives: Osteoarthritis (OA) is a chronic joint disease characterized by osteoproliferation and the degeneration and destruction of articular cartilage. Platelet-rich plasma (PRP) is rich in various growth factors that have been reported to promote bone defect repair. This study examined the specific role and mechanism of PRP in OA. Methods: OA model cells were created by treating articular chondrocytes with IL-1β. After treatment of the model cells with PRP or/and a T-box transcription factor 3 (TBX3)-overexpression plasmid, TBX3 expression was monitored via RT-qPCR, western blotting, and immunofluorescence assays. IL-1β, IL-33, and Caspase-3 levels were detected with ELISA kits. Levels of NLRP3, Caspase-1, MMP9, MMP13, and COL2A1 expression were evaluated by western blotting, and cell proliferation was assessed by the CCK-8 assay. Results: Our results showed that TBX3 expression was upregulated in IL-1β-induced articular chondrocytes. IL-1β stimulation induced inflammation and the production of matrix metalloproteinases, activated Caspase-3 and the NLRP3/Caspase-1 pathway, inhibited the proliferation of articular chondrocytes; however, all those affects mediated by IL-1β could be markedly reversed by PRP. We also found that PRP alleviated IL-1β-induced inflammation, apoptosis, and extracellular matrix degradation in articular chondrocytes by inhibiting TBX3. Our findings suggest that PRP alleviates OA progression in vitro by downregulating TBX3. Conclusion: PRP suppressed OA progression in vitro by inhibiting TBX3, which may be its mechanism of action in treating OA. … (more)
- Is Part Of:
- European journal of inflammation. Volume 20(2022)
- Journal:
- European journal of inflammation
- Issue:
- Volume 20(2022)
- Issue Display:
- Volume 20, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 20
- Issue:
- 2022
- Issue Sort Value:
- 2022-0020-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-05-31
- Subjects:
- Osteoarthritis -- platelet-rich plasma -- T-box transcription factor 3 -- NLRP3/Caspase-1 -- matrix metalloproteinases
Inflammation -- Periodicals
Anti-Inflammatory Agents -- therapeutic use -- Periodicals
Immunotherapy -- Periodicals
Inflammation -- Periodicals
Anti-inflammatory agents -- Periodicals
Immunotherapy -- Periodicals
Anti-inflammatory agents
Immunotherapy
Inflammation
Periodicals
616.0473 - Journal URLs:
- http://eji.sagepub.com/ ↗
http://www.biolifesas.org/blu.htm ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/1721727X221093056 ↗
- Languages:
- English
- ISSNs:
- 1721-727X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24593.xml